作者
Helen Tremlett, Yinshan Zhao, Peter Rieckmann, Michael Hutchinson
发表日期
2010/6/15
来源
Neurology
卷号
74
期号
24
页码范围
2004-2015
出版商
Lippincott Williams & Wilkins
简介
Multiple sclerosis (MS) has entered an era of immunomodulatory drug treatment, the impact of which on long-term disease progression remains controversial. The increasing use of these therapies has intensified our need to understand the true natural history of MS. The MS community is poised to establish whether the immunomodulatory drugs exhibit long-term benefits, with a suitable untreated natural history cohort likely the most practical and ethical comparator group. Thus, a thorough understanding of the natural history of MS is fundamental. In this review, we highlight recent advances in MS natural history over the last 5 years, with a focus on long-term population-based cohorts and factors associated with disease progression. Survival in MS has increased and longer times to irreversible disability have been reported in contemporary studies, indicating a slower accumulation of disability. Wide variation in the …
引用总数
学术搜索中的文章
H Tremlett, Y Zhao, P Rieckmann, M Hutchinson - Neurology, 2010